TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF [0.03%]
TRIM59通过E3泛素连接酶活性依赖的PTRF蛋白K48链多聚泛素化降解促进膀胱癌进展
Junlin Gan,Xuesong Bai,Aijie Zhang et al.
Junlin Gan et al.
Tripartite motif-containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood. In this study, we identified TRIM59 as a clinically relevant oncog...
Proportion of Screen-Detected Gastrointestinal Cancers From the National Cancer Registry in Japan [0.03%]
日本国家癌症登记处通过筛查发现的消化系统肿瘤的比例
Ryuji Okamoto,Yukai Lu,Taisuke Ishii et al.
Ryuji Okamoto et al.
Historically, information on routes of diagnosis in cancer registration in Japan lacked reliability. The launch of the National Cancer Registry in 2016 produced a marked improvement in data accuracy. In this study, we aimed to estimate the ...
Defining Age to Screen and Real-World Effectiveness for Early-Onset Colorectal Cancer [0.03%]
界定结直肠癌筛查的年龄以及早期发病结直肠癌的现实世界有效性
Le Wang,Yu Qiu,Xuechen Chen et al.
Le Wang et al.
Implementation of a RAP-based risk-adapted screening strategy enables personalized screening initiation, with benefits comparable to those observed in the current 50-54-year age group. ...
Myofibroblast-Like CAFs in Metastatic Lymph Nodes Drive Tumor Stemness and Poor Prognosis in Head and Neck Cancer [0.03%]
头颈部癌症转移淋巴结中的肌纤维母细胞样CAF促进肿瘤干细胞特性及不良预后
Hiroyuki Hagiwara,Hideyuki Takahashi,Reika Kawabata-Iwakawa et al.
Hiroyuki Hagiwara et al.
Lymph node (LN) metastasis is one of the major prognostic factors in head and neck squamous cell carcinoma (HNSCC), and treatment sensitivity often differs between primary tumors and metastatic LNs. Beyond tumor cell-intrinsic differences, ...
Genetic Engineering of Tumor-Infiltrating Lymphocytes (TIL) via a T-Editor Platform to Enhance Anti-Tumor Activity [0.03%]
利用T-Editor平台对肿瘤浸润性淋巴细胞(TIL)进行基因编辑以增强其抗肿瘤活性
Fenge Li,Xuejiao Ma,Yongming Xue et al.
Fenge Li et al.
Tumor-infiltrating lymphocytes (TIL) therapy has demonstrated clinical potential in malignancies. However, limited understanding of why only a subset of patients respond to TIL therapy, coupled with the lack of simple and efficient methods ...
Ionizing Radiation and Ultraviolet Light Irradiation-Associated DNA Damage Increasing Genomic Instability Risk [0.03%]
电离辐射和紫外线照射诱导的DNA损伤增加基因组不稳定风险
Ken-Ichi Yoshioka,Yusuke Matsuno,Rika Kusumoto-Matsuo
Ken-Ichi Yoshioka
Cancer frequently develops in association with genomic instability, which includes massive induction of chromosomal structural variants (SVs) and single nucleotide variants (SNVs). SVs are typically caused by erroneous repair of DNA double-...
m6A-Mediated Stabilization of MRPS23 Drives NSCLC Progression Via HSPA8 and ERK Signaling Modulation [0.03%]
通过调节HSPA8和ERK信号,m6A介导的MRPS23稳定促进NSCLC进展
Sihong Le,Yitao Le,Xianshen Sha et al.
Sihong Le et al.
Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to therapeutic resistance and tumor progression. Mitochondrial ribosomal proteins (MRPs), particularly MRPS23, have recently emerged as critical regula...
TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776-Altered Subtype of HER2-Mutant NSCLC [0.03%]
TERT启动子突变与HER2突变型NSCLC的ERBB2 G776改变亚型更相关
Akihiro Yoshimura,Juichiro Yoshida,Chieko Takumi et al.
Akihiro Yoshimura et al.
HER2-mutant non-small cell lung cancer (NSCLC) comprises molecularly heterogeneous tumors with diverse ERBB2 mutation subtypes, and HER2-directed therapies have increased the need for refined molecular stratification. However, subtype-speci...
Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML [0.03%]
Quizartinib耐药突变及FLT3-ITD阳性复发或难治性AML患者治疗预后分析
Yuichiro Semba,Toshihiro Miyamoto,Senji Kasahara et al.
Yuichiro Semba et al.
Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy an...
Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML [0.03%]
Quizartinib耐药突变及FLT3-ITD阳性复发/难治性急性髓系白血病患者治疗结局
Yuichiro Semba,Toshihiro Miyamoto,Senji Kasahara et al.
Yuichiro Semba et al.
Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy an...